Article info

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis

Authors

  • Brigida Anna Maiorano Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy Translational Medicine and Surgery Department, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Rome, Italy PubMed articlesGoogle scholar articles
  • Mauro Francesco Pio Maiorano Department of Biomedical Sciences and Human Oncology, Obstetrics and Gynecology Unit, University of Bari "Aldo Moro", Bari, Italy PubMed articlesGoogle scholar articles
  • Domenica Lorusso Department of Women and Child Health, Division of Gynecologic Oncology, Foundation Policlinic "A. Gemelli" IRCCS, Rome, Italy Scientific Directorate, Foundation Policlinic "A. Gemelli" IRCCS, Rome, Italy PubMed articlesGoogle scholar articles
  • Massimo Di Maio Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy PubMed articlesGoogle scholar articles
  • Evaristo Maiello Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Brigida Anna Maiorano, Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo 71013, Italy; b.maiorano{at}operapadrepio.it
View Full Text

Citation

Maiorano BA, Maiorano MFP, Lorusso D, et al
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis

Publication history

  • Received April 17, 2022
  • Accepted September 15, 2022
  • First published October 13, 2022.
Online issue publication 
November 07, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.